Genakumab reduces the risk of acute gout flares during initiation of urate-lowering therapy: A phase 2, randomized, open-label, multi-center, active-controlled clinical trial
Abstract format and assignment number: Oral presentation OP0299
Date: Friday, 13 June, 10:30 – 10:40
Presenting author: Y. Xue (China)
A single dose (100 or 200 mg) of genakumab, a monoclonal anti-IL1β IgG4 antibody, demonstrated better efficacy and similar safety profile (compared to colchicine 0.5 mg/day) as a prophylaxis against acute gout flares in adults with gout initiating urate-lowering therapy. Notably, in the genakumab 200 mg group, no patient experienced acute gout flare during the entire 12-week period, whereas 21.8% of patients had at least one attack under colchicine.
Safety and Tolerability of Pozdeutinurad (AR882) Treatment following Long-term Dosing in Patients with Chronic Gouty Arthritis and Subcutaneous Tophi
Abstract format and assignment number: Oral presentation OP0300
Date: Friday, 13 June, 10:40 – 10:50
Presenting author: R. Keenan (USA)
In this phase 2 trial of pozdeutinurad, a novel and selective URAT1 inhibitor, long-term treatment alone or in combination with allopurinol for the treatment of tophaceous gout patients was well tolerated, showed comparable safety profile, and better efficacy to allopurinol alone.
Efficacy of a one-stop pharmacist-, dietitian- and nurse-staffed gout clinic versus general care for gout: a retrospective observational study
Abstract format and assignment number: Oral presentation OP0373
Date: Saturday, 14 June, 11:03 – 11:09
Presenting author: W. Lee Wan Hui (Malaysia)
After an initial assessment by a rheumatologist, one-stop gout clinic with a pharmacist, dietitian, and rheumatology nurse outperformed general clinic in achieving target serum uric acid level within a year. Additionally, it showed improved patient compliance and optimization of urate-lowering therapy dosing compared to the general clinic.
Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
Abstract format and assignment number: Oral presentation OP0374
Date: Saturday, 14 June, 11:09 – 11:15
Presenting author: C. Tremblay (Canada)
Based on data from the Early Undifferentiated Polyarthritis (EUPA) cohort, the study suggests that rheumatoid arthritis (RA) patients with at least one radiologic sign suggestive of CPPD in the hands tended to be older and had more comorbidities but appeared to have comparable disease activity and outcomes (except for joint narrowing due to CPPD). However, these patients required more intensive treatment with conventional and biologic DMARDs and glucocorticoids.
Ufuk Ilgen
Ufuk is a rheumatologist. Currently, he is doing his MSc in Translational Medical Research Programme at Heidelberg University, Germany. His main interests are the immunopathological background of autoimmune diseases, hereditary fever syndromes and amyloidoses, and endothelial cell biology. He is a member of the Turkish Society for Rheumatology and European Lupus Society.
He is a member of the EMEUNET Country Liaisons Sub-Committe.